APOPTOSIS INDUCING AGENTS FOR TREATING CANCER AND IMMUNE AND AUTOIMMUNE DISEASES Russian patent published in 2015 - IPC C07C311/51 C07D207/36 C07D211/96 C07D231/18 C07D261/10 C07D275/03 C07D277/36 C07D277/60 C07D285/125 C07D285/135 C07D295/155 C07D295/26 C07D333/34 C07D333/36 C07D333/42 C07D333/62 C07D409/12 C07D413/04 C07D413/06 C07D417/14 C07D487/04 C07D513/04 A61K31/18 A61K31/404 A61K31/4465 A61K31/415 A61K31/42 A61K31/422 A61K31/425 A61K31/426 A61K31/428 A61K31/429 A61K31/433 A61K31/5375 A61K31/381 A61K31/519 A61P35/00 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of formula or its therapeutically acceptable salts, wherein A¹ represents furyl, imidazolyl, isothiazolyl, isoxazolyl, pyrazolyl, pyrrolyl, thiazolyl, thiadiazolyl, thienyl, triazolyl, piperidinyl, morpholinyl, dihydro-1,3,4-thiadiazol-2-yl, benzothien-2-yl, banzothiazol-2-yl, tetrahydrothien-3-yl, [1,2,4]triazolo[1,5-a]pyrimidin-2-yl or imidazo[2,1-b][1,3]-thiazol-5-yl; wherein A¹ is unsubstituted or substituted by one, or two, or three, or four, or five substitutes independently specified in R¹, OR¹, C(O)OR¹, NHR¹, N(R¹)₂, C(N)C(O)R¹, C(O)NHR¹, NHC(O)R¹, NR¹C(O)R¹, (O), NO₂, F, Cl, Br and CF₃; R¹ represents R², R³, R⁴ or R⁵; R² represents phenyl; R³ represents pyrazolyl or isoxazolyl; R⁴ represents piperidinyl; R⁵ represents C₁-C₁₀alkyl or C₂-C₁₀alkenyl each of which is not specified or specified by substitutes specified in R⁷, SR⁷, N(R⁷)₂, NHC(O)R⁷, F and Cl; R⁷ represents R⁸, R⁹, R¹⁰ or R¹¹; R⁸ represents phenyl; R⁹ represents oxadiazolyl; R¹⁰ represents morpholinyl, pyrrolidinyl or tetrahydropyranyl; R¹¹ represents C₁-C₁₀alkyl; Z¹ represents phenylene; Z² represents piperidine unsubstituted or substituted by OCH₃, or piperazine; both Z^1A and Z^2A are absent; L¹ represents C₁-C₁₀alkyl or C₂-C₁₀alkenyl each of which is unsubstituted or substituted by R^37B; R^37B represents phenyl; Z³ represents R³⁸ or R⁴⁰; R³⁸ represents phenyl; R⁴⁰ represents cyclohexyl or cyclohexenyl; wherein phenylene presented by Z¹ is unsubstituted or substituted by the group OR⁴¹; R⁴¹ represents R⁴² or R⁴³; R⁴² represents phenyl, which is uncondensed or condensed with pyrrolyl, imidazolyl or pyrazole; R⁴³ represents pyridinyl, which is uncondensed or condensed with pyrrolyl; wherein each cyclic fragment presented by R², R³, R⁴, R⁸, R⁹, R¹⁰, R³⁸, R⁴⁰, R⁴² and R⁴³ is independently unsubstituted or substituted by one or more substitutes independently specified in R⁵⁷, OR⁵⁷, C(O)OR⁵⁷, F, Cl CF₃ and Br; R⁵⁷ represents R⁵⁸ or R⁶¹; R⁵⁸ represents phenyl; R⁶¹ represents C₁-C₁₀alkyl; and wherein phenyl presented by the group R⁵⁸ is unsubstituted or substituted by one or more substitutes independently specified in F and Cl.

EFFECT: invention refers to a pharmaceutical composition containing the above compounds, and to a method of treating diseases involving the expression of anti-apoptotic Bcl-2 proteins.

7 cl, 2 tbl, 48 ex